Research & Development
Broad Institute, Dana-Farber, St. Jude Children's Research Hospital collaborate on pediatric cancers
The organizations said they will invest more than $60 million over five years to support a collaboration called the Pediatric Cancer Dependencies Accelerator project.
October 13, 2022
How has the COVID-19 pandemic affected pediatric care?
Elhadi, an assistant professor of health, behavior, and policy at the university discussed his research on the impact of the COVID-19 pandemic on pediatric cancer patients with LabPulse.com at the recent American Association for Cancer Research (AACR) meeting in New Orleans.
May 2, 2022
Genetic testing promises better prognosis for pediatric cancer patients
The multinational study evaluated outcomes in pediatric oncology patients with relapsed cancer and a poor prognosis who were tested and then directed to targeted treatments in accordance with their individual genetic profile. Results were presented in a late-breaking abstract and highlighted in the press program of the ASCO meeting, which is being held in a virtual format from May 29 to 31.
May 28, 2020
ASCO previews cover molecular screening for kids, TMB biomarkers | Liquid biopsy results | New tests for babesiosis
Dear LabPulse Member,
May 20, 2019
So far, so good with NCI pediatric molecular screening study
Out of 422 children, adolescents, and young adults (up to the age of 21) with relapsed/refractory cancers enrolled in the NCI-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice (NCI-COG Pediatric MATCH) study, tumor samples were taken for 390, or 92%. Of those who had their tumors sequenced, 24% were eligible for treatment with a targeted therapy available through the study, and 10% had been enrolled in a trial as of the end of 2018, the investigators reported in an interim analysis ahead of the ASCO meeting, which is scheduled to be held from May 31 through June 4 in Chicago.
May 15, 2019
Next-generation sequencing offers hope for kids with cancer
Molecular profiling helped identify genetic mutations that could be acted upon in 54 out of 62 children and adolescents whose tissue could be evaluated in the Personalized Targeted Therapy in Refractory or Relapsed Cancer in Childhood (TRICEPS) study, reported Fida Khater, PhD, and colleagues at the Centre Hospitalier Universitaire Sainte-Justine in Montreal.
April 28, 2019
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
Quest Diagnostics completes acquisition of Summa Health outreach lab services business
Page 1 of 1